Zacks
  • Home
  • Analyst Bios
  • Research Reports
    • Companies by Analyst
      • Biotech - David Bautz, PhD
      • Bank & Finance – Ann Heffron, CFA, CPA
      • Biotech - John Vandermosten, CFA
      • Special Situations – Steven Ralston, CFA
      • Med-Tech – Brian Marckx, CFA
      • Technology – Lisa Thompson
      • Senior Analyst – M. Marin
      • Healthcare - Beth Senko, CFA
    • Companies by Name
  • Distribution
    • Institutional Distribution
    • Retail Distribution
    • Social Media
    • RSS Feeds
  • Our Partners
    • IR Firms
  • Contact
  • Subscribe
    • Free Weekly Digest
    • Zacks SCR Premium
M. Marin, Senior Analyst

M. Marin has over 15 years of sell-side research experience, having begun her financial research career at Oppenheimer and Morgan Stanley. She has been recognized by the Wall Street Journal's "Best on the Street" and Institutional Investor's analyst ranking survey. In partnership with Soleil Securities, M. founded and ran her own independent research boutique where she focused on the digital media sector. Prior to that, she held senior research positions at Salomon Brothers, ING Barings and Bear Stearns.


At Zacks, she focuses on the Technology and Life Sciences space, following companies in both the medical device and drug development areas. Reflecting her extensive experience and understanding of the path to commercialization of a new device and/or drug candidate, M. Marin's approach to analyzing investment opportunities along the way can help investors understand the pipeline and potential. Having spent time focused on the investor relations and corporate communications sides of the business, she can communicate the issues to investors in a way that generalists and specialists alike can appreciate.


M. Marin holds a B.A. in economics from Swarthmore College and has completed the coursework for a Masters of Business Administration candidate at New York University.

M. Marin's Universe Includes







































Latest

Notes in the Press

March 4, 2021 BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing…
March 3, 2021 Deep Yellow Limited Releases Positive PFS with Maiden Reserve on Tumas Project; Board Approves Proceeding Directly to a DFS
March 2, 2021 TRC: Recent Updates Imply Strong Positives For Development Plans
March 1, 2021 IDBA: Idex Biometrics Reports 2020 Earnings and Lists on NASDAQ
March 1, 2021 ELYS: Expanding Strategic Relationship to Leverage Growth Opportunities
March 1, 2021 ACHV: Data Presentation on Smoker and E-Cigarette User Attitudes and Quitting Perceptions
March 1, 2021 DSS Establishes a JV to Pursue a Digital Securities Exchange in the US and Adds Marketing Partners
March 1, 2021 KTRA: 2Q:21 Update & Target Price Increase
March 1, 2021 CVM: 1Q:21 Financial Update
March 1, 2021 BIOX: Bioceres Crop Solutions is poised to benefit from regulatory approvals in China for HB4 soybeans and in Brazil for HB4 wheat
 

Invalid login, please try again. You have retries remaining before your account will be locked.

Your account is locked and it will be unlocked automatically in minutes.

User ID:
Password:
Remember my ID:

COPYRIGHT © ZACKS INVESTMENT RESEARCH 2020
  • Disclaimer
  • Privacy Policy
  • Site Map
Tweet Follow @ZacksSmallCap
Powered By Q4 Inc. 5.52.0.6